Amplification of MYCN in neuroblastoma strongly correlates to unfavorable outcome, but little is known of how the high MYCN expression translates into an aggressive tumor phenotype. More aggressive neuroblastomas are generally immature and overexpression of exogenous MYCN in cultured neuroblastoma cells and other neuronal cell types has been reported to inhibit induced differentiation, suggesting a link between high MYCN expression and an immature phenotype. However, we show here that MYCN is expressed in human neuroblasts of sympathetic chain ganglia at fetal week 8.5, a developmental stage at which these neuroblasts express a number of sympathetic neuronal differentiation marker genes. Analyses of 28 neuroblastoma tumor specimens and 27 cell lines for the expression of MYCN and a panel of neuronal differentiation marker genes did not reveal any correlation between MYCN and marker gene expression levels. Finally, we tested five separate differentiation protocols and show that MYCN overexpressing neuroblastoma cells with a neuronal phenotype, derived from the non-MYCN-amplified human neuroblastoma cell line SK-N-SH, retain their capacity to differentiate despite constitutive MYCN overexpression. Our results show that high MYCN expression and sympathetic differentiation are compatible, and indirectly our findings lend support to previously published MYCN neuroblastoma tumor data, which suggest that in single MYCN copy neuroblastomas there is no direct correlation between a high cellular MYCN protein content and aggressive tumor cell behavior.
The MYC family consists of three closely related transcription factors encoding the proto-oncogenes MYC, MYCN, and MYCL (also known as MYCC or c-myc, N-myc, and L-myc, respectively). MYC is the founding member, whose transforming properties were first evidenced by the pioneering studies on avian retroviruses. Subsequently, increased expression of MYC oncogenes due to translocations or genomic amplification was detected in various human neoplasms. Over the past 15 years, evidence has accumulated supporting a role for MYC in a variety of cellular pathways controlling cell growth, differentiation, cell adhesion, angiogenesis, apoptosis, immortalization, and genome stability.
Amplification of MYCN occurs in a number of childhood and adult tumors and is a hallmark of a genetic subgroup (22% of all cases 1-7 ) of highly aggressive neuroblastomas, that is, pediatric sympathetic nervous system-derived tumors. Early on, MYCN amplification was recognized as an independent prognostic factor for neuroblastoma and was used as one of the first genetic markers in therapy stratification for cancer treatment. In parallel to observations for MYC, increased MYCN expression was thought to be essential for constituting the malignant phenotype. Consistent with this assumption, overexpression of MYCN, targeted to sympathetic precursor cells via the tyrosine hydroxylase promoter in transgenic mice, results in the development of tumors with neuroblastoma characteristics. 8 Recent evidence for a role in perturbed growth control came from the finding that postmitotic sympathetic neurons could be induced by MYCN to re-enter the S phase of the cell cycle. 9 Furthermore, overexpression of MYCN in the epithelial neuroblastoma subclone SH-EP resulted in increased DNA synthesis and growth rate. 10 An extended expression analysis of these cells, in which the MYCN gene is under a controllable promoter, revealed that the majority of MYCN-induced genes are regulators of protein synthesis, and many of these genes were also induced by MYC in melanoma cells. 11 Insights into the role of MYCN in differentiation and tumor development might indirectly be deduced from our current knowledge of MYC, although evidence indicates separate roles for the MYC family members. The identification and, in particular, the validation of MYC and MYCN target genes and the dissection of the cellular network governed by both genes, has, however, proven extremely difficult and our understanding of the exact role of MYC or MYCN in the abovementioned pathways is, as yet, poor. In normal avian and murine development, MYCN is expressed preferentially during early embryogenesis with high expression at the time of organogenesis. 12, 13 In general, major sites of MYCN expression correlate to regions of differentiating cells, rather than to areas with high proliferation rates. [13] [14] [15] Of particular relevance for the present study is the high MYCN expression in neural crest-derived progenitor cells. In avian cells, a role for MYCN in controlling cell migration and neuronal determination or early differentiation of neural crest-derived cells is suggested. 16 In mice, homozygous elimination of MYCN is lethal and the sympathetic nervous system (SNS) has fewer neuroblasts, but those that remained appeared to develop normally. 17 These observations from developmental studies are, however, contrasted by reports of blocked retinoic acid (RA)-induced differentiation and growth arrest by exogenous MYCN overexpression in neuroblastoma cell lines carrying an amplified MYCN gene. 18, 19 As MYCN amplification is closely associated to high-stage neuroblastomas and an inverse correlation between clinical neuroblastoma stage and the expression of differentiation marker genes has been established, 20 a role for MYCN in differentiation arrest can be inferred. However, although MYCNamplified neuroblastoma tumors consistently show increased MYCN expression both at the mRNA and the protein level, [21] [22] [23] a closer examination reveals that MYCN single-copy low-stage neuroblastoma tumors (stages 1, 2, and 4S) also can express high MYCN levels, seemingly without affecting either the malignant status of the tumor or patient outcome. In contrast, some, but not all, reports on non-MYCNamplified tumors at higher clinical stages conclude that high MYCN expression correlates to poor outcome. [24] [25] [26] In this report, we have addressed the putative role of MYCN in blocking neuronal differentiation of human neuroblastoma cells. We have analyzed the expression levels of MYCN and correlated them to the expression of established sympathetic neuronal/ neuroendocrine marker genes in a panel of neuroblastoma cell lines and tumor specimens. We have further used MYCN-transfected clones of SK-N-SH neuroblastoma cells, 27 which are non-MYCN amplified and have the rare capacity to differentiate neuronally by several different protocols, to study the effect of overexpression of MYCN on induced differentiation. Taken together, our tumor and cell line data strongly suggest that the overall capacity of neuroblastoma cells to undergo neuronal differentiation is not impaired by high MYCN expression.
Materials and methods

Tumor Material, Cell Lines, and Cell Culture Conditions
The clinical material consisted of 13 stage 1, 2, and 4S tumors and 15 stage 3 and 4 tumors. Seven of them had an amplified MYCN gene. SK-N-SH, SH-SY5Y, KCN-69n, and SK-N-BE (2) cells were cultured in Eagle's minimum essential medium with 10% fetal calf serum, 100 IU/ml penicillin V, and 100 mg/ml streptomycin added. SH-EP cells were supplied with the same medium and antibiotics, but with 15% fetal calf serum. All other neuroblastoma cell lines were cultured in RPMI 1640 with 10% fetal calf serum and antibiotics as above. The SKMYC2 clone of SK-N-SH cells transfected with human MYCN has previously been described. 27 Briefly, MYCN cDNA (from pcNMYC3, Dr JM Bishop, University of California, San Francisco, CA, USA) was cloned into an RSV-LTR-driven expression vector in either sense or antisense orientation. Stable transfectants were achieved using calcium-phosphate precipitation and selection for expression of the hygromycin resistance gene also on the pREPcNMYC2 (sense) and pREPcNMYCAS2 (antisense) plasmids. The cells were then cultured as SK-N-SH cells with 200-600 mg/ml Hygromycin B (Calbiochem, San Diego, CA, USA) added. To induce differentiation, the following additives were used: All-trans-retinoic acid (RA) (Sigma, St Louis, MO, USA), aphidicolin (Sigma), 12-O-tetradecanoyl-phorbol-13-acetate (TPA) (Sigma), basic fibroblast growth factor (bFGF), brainderived neurotrophic factor (BDNF), insulin-like growth factor-I (IGF-I), and nerve growth factor (NGF), all growth factors from PeproTech EC Ltd, London, England. Media and antibiotics were purchased from Life Technologies Inc (Rockville, MD, USA), and fetal calf serum from PAA Laboratories GmbH, Linz, Austria.
Immunohistochemistry and In situ Hybridization
Human fetal tissue (ethical approval LU 389-98, Lund University, Sweden) was obtained from elective abortions and the material was fixed in formaldehyde and paraffin embedded. Abdominal cross-sections (5 mm thick) were secured onto glass slides and deparaffinized. Immunohistochemistry was performed as described, 28 using avidin-biotinperoxidase conjugated secondary antibodies (ABCkit, Vectastain, Vector Laboratories, Burlingame, CA, USA) and diaminobenzidine as chromogen. The primary antityrosine hydroxylase (TH) monoclonal antibody (Roche Molecular Biochemicals, Mannheim, Germany) was used at a 1:75 dilution. Slides were counterstained with hematoxylin. For in situ hybridizations, sections were pretreated as described. 29 MYCN RNA transcripts were detected with an antisense-oligonucleotide mouse sequence probe, with hybridization conditions essentially as described. 30 The following oligonucleotides were used: Antisense probe: 5 0 -AAG TAG AAG TCA TCT TCG TCC GGG TAG AAG CAG GGC TGC A-3 0 , sense probe: 5 0 -CGA TTT CCT CCT CTT CAT CTT CCT CCT CGT CAT CCT CAT C-3 0 (Invitrogen AB, Stockholm, Sweden, custom-made primers). The oligonucleotides were 3 0 -endlabeled with 35 S-dATP using terminal deoxyribonucleotidyl transferase. The sections were hybridized at 421C overnight and washed four times in 1 Â SSC at 561C. The sense probe was used as hybridization control.
Immunofluorescence and Western Blot Analyses
Cells intended for immunofluorescence were plated on glass coverslips, treated as described in the Results section, fixed with 4% paraformaldehyde in PBS, and mounted on object slides with 20 ml PVA-DABCO solution (9.6% polyvinyl alcohol, 24% glycerol, and 2.5% 1,4-diazabicyclooctane in 67 mM Tris-HCl, pH 8.0). TBS with 5% goat serum and 0.3% Triton X-100 was used as blocking and permeabilization buffer, anti-MYCN antibody (556438 from BD Pharmingen, San Diego, CA, USA) diluted 1:100 in blocking and permeabilization buffer as primary, and goat anti-mouse IgG-FITC-conjugated antibodies (Alexa Fluor 488, Molecular Probes, Inc., Eugene, OR, USA) diluted 1:100 in TBS as secondary antibodies. The results were documented with or without FITC-filters, using a SONY DKC 5000 camera system (Sony Corporation, Tokyo, Japan). For Western blot analysis, cells were lysed in 10 mM Tris-HCl (pH 7.2), 160 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 1 mM EGTA, 1 mM EDTA in the presence of complete protease inhibitor (Roche). A measure of 40-60 mg of whole-cell lysate proteins were separated on an SDS-PAGE gel and blotted onto an Immobilon-P membrane (Millipore Corporation, Bedford, MA, USA). The following primary antibodies were used: anti-actin antibody (ICN Biomedicals Inc., Costa Mesa, CA, USA), diluted 1:2500 and anti-MYCN antibody (556438 from BD Pharmingen) diluted 1:500. HRP-coupled secondary antibody fragments were supplied from Bio-Rad Laboratories, Hercules, CA, USA (diluted 1:3000) or Amersham Pharmacia Biotech, Uppsala, Sweden (diluted 1:5000). Rainbow RPN 756 (Amersham) was used as a molecular weight marker.
Northern Blot and Quantitative RT-PCR Analyses
A commercial guanidine-isothiocyanate/phenolchloroform extraction solution (Trizol, Invitrogen Inc., Carlsbad, CA, USA) was used for isolation of total cellular RNA. For Northern blot analysis, 15 mg of RNA was electrophoretically separated on a 1% agarose-formaldehyde gel and blotted onto a nylon membrane (Hybond-N, Amersham 2 Hybridizing probes were visualized by autoradiography (Curix Blue HC-S Plus, Agfa-Gevaert N.V. Mortsel, Belgium). DNase treatment, cDNA synthesis, primer design, and SYBR Green I real-time quantitative RT-PCR were performed as described 35 with minor modifications. After establishment of amplification efficiencies 495% for all primer pairs, the comparative Ct method was used for quantification. PCR reagents were obtained from Eurogentec as SYBR Green I mastermixes and used according to the manufacturer's instructions in a total volume of 25 ml. Reactions were run on an ABI5700 (Applied Biosystems) in duplex (coefficient of variation for calculated quantities always below 10%). Gene expression levels were normalized using the geometric mean of the four most stable internal control genes in neuroblastoma (ie UBC, HPRT1, SDHA, and GAPD) as reported previously.
36 Primer sequences for all tested genes are available in the public RTPrimerDB database (http://www.realtimeprimerdatabase.ht.st) (gene (RTPrimerDB-ID):
Results
MYCN is Expressed in Developing Human Sympathetic Neuroblasts
To verify that MYCN is expressed during development of the human SNS, MYCN expression was analyzed in abdominal cross-sections of an 8.5-week-old human fetus. At this developmental stage, sympathetic chain ganglia are under formation and TH-positive sympathetic precursor cells are populating the developing adrenal glands ( Figure 1c ). As shown in Figure 1a and b, strong MYCN expression was detected in dorsal root ganglia, sympathetic chain ganglia, and in the spinal cord. Interestingly, the migrating sympathetic adrenal precursor cells appeared not to express MYCN, or are at the most expressing MYCN modestly (compare TH-positive cells in panel c with the in situ signal in the corresponding areas in panels a and b). we conclude that human sympathetic chain ganglion neuroblasts express MYCN at a stage when these cells are nonmigrating and when they express a number of sympathetic neuronal marker genes.
38-40
Expression of MYCN and Neuronal Marker Genes in Neuroblastoma Cells and Tumors
The stage of differentiation based on morphological criteria has for a long time been used as a prognostic factor in neuroblastoma, and in line with this, expression levels of differentiation markers such as neuron-specific enolase, synaptophysin, and the neuronal form of pp60 c-src correlate positively to favorable outcome. 20, 41 . MYCN amplification is associated with an aggressive phenotype and when MYCN is overexpressed in MYCN-amplified cultured neuroblastoma cells, RA differentiation is blocked. 18, 19 However, as the link between MYCN expression and prognosis or tumor stage in non-MYCN-amplified neuroblastomas is contradictory, 25, 42 we analyzed a panel of neuroblastoma cell lines and tumor specimens for the expression of MYCN and a set of SNS differentiation markers by quantitative real-time RT-PCR (Figure 2 ). In the 27 analyzed cell lines, the highest MYCN expression was found in those derived from MYCN-amplified tumors. Similarly, in the panel of 28 investigated tumor specimens, MYCN expression was, with one exception, highest in tumors with an amplified gene ( Figure 2 ). The five analyzed SNS neuronal/neuroendocrine differentiation marker genes, HAND2 (dHAND), NTRK1 (trkA), GAP43, STMN2 (SCG-10), and CHGA (chromogranin A), were with few exceptions expressed in all cell lines, which first of all confirms the SNS and neuroblastoma derivation of the analyzed tumor cell lines. However, there was no correlation between MYCN expression and the expression levels of the differentiation markers (Table 1) , 44 which can be demonstrated visually by ordering the cell lines according to MYCN expression levels ( Figure 2) . A similar result was obtained with tumor specimens when MYCN expression was compared to the expression levels of HAND2, NTRK1, and GAP43 (Table1 and Figure 2) ; the mRNA levels of STMN2 and CHGA were not measured. We conclude that MYCN expression did not correlate, positively or negatively, to the stage of differentiation in neuroblastoma. As a comparison, PCR data demonstrating a statistically significant negative correlation between MYC and MYCN expression were included (Table 1 , and as previously reported 43, 44 ).
Overexpression of Exogenous MYCN in SK-N-SH Neuroblastoma Cells
We next wanted to test whether overexpression of MYCN could affect induced differentiation of cultured neuroblastoma cells lacking MYCN amplification. In order to test this, we had to work in a non-MYCN-amplified cell system with the potential to differentiate neuronally, which excludes most, if not all, neuroblastoma cell lines currently available. We chose to work with SKMYC2 cells, which are SK-N-SH cells stably transfected with MYCN, for two major reasons: (i) the parental cells have the capacity to differentiate in response to a number of different treatment protocols, and (ii) the differentiated phenotypes are well characterized. To our knowledge, there is no other non-MYCN-amplified neuroblastoma cell line that meets these criteria. Furthermore, these transfected cells can be grown and selected in such a way that a majority of the cells retain their neuroblastic features, although the cultures always contain a small fraction of surface adherent, S-type-like cells. 27, 45 In Figure 3 , the MYCN expression in SKMYC2 and in neuroblastoma this study was functional (Figure 3a and c) . The functionality of the transfected MYCN construct has further been demonstrated in previous studies showing altered b1 integrin subunit and NCAM levels, indicating that the normal integrin-dependent growth regulation had been short-circuited, a phenomenon not observed in mock-transfected cells. 27, 47, 48 The SKMYC2 parental cell line, SK-N-SH, contains three morphologically distinct and interconvertible cell types, the N-type with neuroblastic properties (represented by the SH-SY5Y subclone), the surface-adherent S-type (represented by the SH-EP subclone), and intermediate forms, I-type cells. 49 In SK-N-SH cultures, N-type cells dominate and have the capacity to differentiate neuronally. 50 Stype cells virtually lack neuronal properties and the capacity to differentiate neuronally. In general, SKMYC2 cell cultures contained a smaller proportion of N-type cells than did cultures of untrans- 
RA-and TPA-induced Differentiation of SKMYC2 Cells
To investigate if MYCN overexpression affects induced neuronal differentiation of neuroblastoma cells, SKMYC2, SK-N-SH, SH-SY5Y, and SH-EP cells were treated with 1 mM RA or 16 nM TPA, treatments previously shown to differentiate SH-SY5Y and SK-N-SH cells. 50, 51 . Addition of either TPA or RA (Figure 5a -f) to SKMYC2 cultures led to morphological differentiation of MYCN expressing N-type cells, seen as an extension of neurites with growth cones and varicosities, while S-type cells appeared unaffected. In line with these and previous SKMYC2 cells treated with RA and TPA were analyzed for the expression of the neuronal marker genes NPY and GAP43, using SH-SY5Y and SH-EP cells as references. TPA treatment led to an increased expression of NPY in SH-SY5Y as well as in SKMYC2 cells. Treatment with RA resulted in a downregulation of NPY expression in both cell systems (Figure 6a) , consistent with the development of a cholinergic phenotype, as demonstrated previously. 52, 53 The SH-SY5Y response was more pronounced and mimicked that of the SK-N-SH cells (Figure 6a and b) . SH-EP did not express NPY regardless of treatment. Treatment with RA resulted in a slight upregulation of the GAP43 expression in SH-SY5Y, SKMYC2, and SK-N-SH cells, while TPA clearly upregulated GAP43 in these cells (Figure 6a and b), as previously reported in SH-SY5Y cells. 53, 54 The NPY expression in the TPA-treated SKMYC2 cells was low compared to the expression in the correspondingly treated SK-N-SH and SH-SY5Y cells (Figure 6a and b) . This difference could be explained by the comparatively high proportion of S-type cells, expressing low amounts of NPY, present in the SKMYC2 cultures. To estimate the Figure 4 Morphology and MYCN expression in neuroblastoma cell lines. SKMYC2 cells grown in serum-containing medium and analyzed at a low cell density, day 1 ((a), (b)), and at a higher cell density at day 6 ((c), (d)). Cell morphology was assessed using phase-contrast microscopy ((a), (c)) and nuclear MYCN expression was detected by immunofluorescence ((b), (d). SH-EP ((e), (f)) and SK-N-SH ((g), (h)) cells grown for 3 days in serum-containing medium and analyzed by phase-contrast microscopy ((e), (g)) and for MYCN expression by immunofluorescence ((f), (h)). mRNA contribution from S-type cells, HES1 expression was analyzed as HES1 mRNA is abundant in SH-EP cells, but no or little mRNA can be detected in SH-SY5Y cells (Figure 6a and Grynfeld et al 33 ). As shown in Figure 6a , the SKMYC2 cells had higher HES1 mRNA levels than the SH-SY5Y cells, confirming a substantial contribution of S-type cell mRNA in these assays.
Growth Factor-induced Differentiation of SKMYC2 Cells
To extend the analysis of the capacity of the SKMYC2 cells to differentiate, we utilized additional protocols known to induce differentiation of SH-SY5Y cells, including protocols employing growth factors of importance in normal sympathetic development. [55] [56] [57] SKMYC2 and SK-N-SH cells were treated with 1 mM RA or a combination of 1 mM RA and 100 ng/ml BDNF, which induced neurite outgrowth of neuroblastic but not S-type cells in both SK-N-SH and SKMYC2 cultures (Figure 5g, h, s and t) . Notably, the differentiated SKMYC2 cells retained a nuclear MYCN staining, suggesting that they differentiated despite a high MYCN expression ( Figure  5h) . Following another published differentiation protocol, the cells were treated with 3 nM bFGF and 5 nM IGF-I. 56 Both SKMYC2 and SK-N-SH cells differentiated morphologically in response to these growth factors, and nuclear staining of MYCN was again seen in SKMYC2 cells with long neurites (Figure 5i,j,u and v) . Finally, the cells were differentiated with NGF (100 ng/ml) in combination with aphidicolin (0.3 mM), a cell cycle blocking agent, which induces NTRK1 expression and NGF responsiveness in SH-SY5Y cells. [57] [58] [59] As aphidicolin blocks cell division, the number of cells in these cultures was comparatively low and N-type neuroblastoma cells were few. However, the cells present extended long neurites in the presence of NGF (Figure 5k ,l,w and x), and the differentiated SKMYC2 cells retained a nuclear MYCN staining pattern (Figure 5l) . Interestingly, the aphidicolin/ NGF-treated SKMYC2 cells had considerably longer neurites than SK-N-SH cells treated in the same way (data not shown).
Differentiating SKMYC2 Cells Retain a High MYCN Expression
Neuroblastoma cells endogenously overexpressing MYCN as a result of gene amplification downregulate MYCN during induced differentiation. [55] [56] [57] To exclude the possibility that the effect of exogenous MYCN was lost due to downregulation of MYCN in differentiating SKMYC2 cells, MYCN expression levels were analyzed in more detail. The MYCNamplified SK-N-BE (2) cells, which differentiate with RA, served as a positive control. In cells treated for 3 and 6 days, MYCN protein levels decreased slightly, as expected (Figure 7a ), while the expression in SKMYC2 cells was virtually unaffected when treated with 1 or 10 mM RA. Furthermore, SK-N-SH, SKMYC2, and SH-EP cells treated with TPA or RA for 3 days were analyzed for MYCN protein content. Neither of the treatments substantially changed the MYCN protein levels (Figure 7a and b), in agreement with mRNA expression and immunofluorescence data in Figures 5 and 6 .
Discussion
The important role of MYCN in early embryonal development is illustrated by profound disturbances and early embryonic death of homozygous MYCN knockout mice. However, the role of MYCN in cellular differentiation in relation to neuroblastoma development has not yet been fully addressed. Detailed MYCN expression studies performed in mice show that MYCN is preferentially expressed at sites with ongoing cell differentiation, tissue maturation, and organogenesis. [13] [14] [15] In agreement with these results, we recently observed that in human neuroblastoma cells the loss of a differentiated phenotype induced by hypoxia was paralleled by MYCN downregulation in all studied MYCN-amplified cell lines. 60 We have found that MYCN is expressed in human sympathetic neuroblasts at a comparatively late developmental stage (week 8.5). Clearly, neuroblasts are at this stage committed to sympathetic neuronal development and express several sympathetic marker genes such as TH, HAND2, GAP43, NPY, BCL2, and STMN2. [38] [39] [40] Unlike most neuroblastoma cells, these neuroblasts have passed the stage of ASCL1 (HASH-1) expression. 40 ASCL1 is involved in the determination of the sympathetic ganglionic lineage, 61 suggesting that normal sympathetic neuronal differentiation beyond the stage at which most neuroblastoma cells appear to be arrested proceeds in the presence of a significant MYCN expression.
To further investigate the putative role of MYCN in controlling cellular differentiation, we analyzed the phenotypic response of non-MYCN-amplified neuroblastoma cells with constitutive exogenous overexpression of MYCN to several established differentiation protocols. Under all conditions, these cells were shown to retain their capacity to differentiate morphologically. In none of these settings, the differentiation was accompanied by any substantial reduction of MYCN mRNA or protein levels, clearly indicating that differentiation could proceed in the presence of high MYCN expression. We further studied the expression levels of well-established sympathetic nervous system neuronal/neuroendocrine differentiation markers in neuroblastoma cell lines and tumors. Our results clearly demonstrate an absence of correlation between the expression levels of differentiation markers and MYCN, suggesting the results from the SKMYC2 system to be relevant also in vivo.
These findings appear to contradict in vitro data demonstrating that overexpression of MYCN in human neuroblastoma cells and rat cells derived from the brain blocks induced differentiation. 18, 19, 62 A role for the maintenance of the immature phenotype is also suggested by the high incidence of MYCN amplification and overexpression in a subset of high stage, less-differentiated neuroblastomas. Overexpression of MYCN in non-MYCNamplified neuroblastoma cells and the impact on differentiation have not been studied in a neuronal context, as previous MYCN overexpression studies in non-MYCN-amplified neuroblastoma cells have mainly utilized SH-EP cells. 10, 11, 19 These cells virtually lack neuroblastic properties (Ross et al, 49 Rettig et al 63 and this report) and cannot be induced to differentiate neuronally by existing differentiation protocols (this report and unpublished observations). Thus, this cell system would not be expected to be informative when studying putative effects of MYCN on differentiation into a neuronal sympathetic neuroblastoma phenotype. Nor does the recently published study in which MYCN overexpression in rat postmitotic sympathetic neurons elicited the capacity of these cells to re-enter cell cycle (but not enhanced survival) necessarily exclude a specific role for MYCN during differentiation. 9 It is possible that the differences in outcome between the present study and the studies using MYCN-amplified cell lines 18, 19 result from differences in the total MYCN expression levels and that extreme levels of MYCN expression will antagonize a neuronal sympathetic phenotype, thus assuming a functional threshold for this effect of MYCN. 6 This would be in line with a recent report showing that overexpression of MYCN can block terminal differentiation of sensory neurons. 64 However, the MYCN protein content in the SKMYC2 cells is in parity with that of some neuroblastoma cell lines with amplified MYCN and, more importantly, no signs of a correlation between MYCN expression and expression of differentiation marker genes in neuroblastoma tumors and cell lines could be detected. This was true even when only those tumors with the highest MYCN expression were considered. In vivo, not only the absolute level of expression, but also the regulation of expression, for example, in response to stress has to be considered. In this respect, the behavior of SKMYC2 cells might be expected to be closer to that of MYCN-amplified cells than that of high MYCN expressing cells without MYCN amplification.
If the link between MYCN amplification and poor prognosis cannot be explained by blocked differentiation, what are the alternative explanations? It has been shown that MYCN can functionally replace MYC in murine development 65 and we can assume that MYCN, like MYC, is involved in a variety of pathways that, when disturbed, can contribute to cancer development. Presumably, the pathways affected vary depending on the differentiation status and the presence of additional genetic changes. Furthermore, MYCN amplification is a result of genetic instability, which in itself is associated with poor prognosis and tumor progression. The picture is further obscured by the fact that the varying MYCN expression seen in low-stage neuroblastomas might instead reflect the differentiation and proliferation status of the tumor cells. In view of this limited understanding of the molecular basis of MYCN gene regulation and the possibility that MYCN forms an integral part of a subtle transcriptional network, dependent on cell type and differentiation status, we can only speculate on the exact nature of the role of MYCN in neuroblast differentiation. Thus, further experiments using different overexpressing systems in parallel with identification of bona fide MYCN target genes are needed. However, the data presented here strongly suggest that expression of MYCN is compatible with normal sympathetic neuronal development and that neuronal differentiation of neuroblastoma cells is not blocked by high MYCN levels.
